Skip to main content

Table 1 Relation between CD9, CD63 and CD82 expression and various prognostic factors

From: Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma

clinicopathological characteristics No. of patients CD9     CD63     CD82    
   transcript   protein   transcript   protein   transcript   protein  
Gender   avarage p-value average p-value avarage p-value average p-value avarage p-value average p-value
Male 29 83.10 0.707 3.11 0.238 112.56 0.616 4.40 0.009 87.90 0.66 3.19 0.54
Female 20 82.31   4.06   110.12   3.00   80.47   2.64  
Age              
≤65 20 81.10 0.867 3.78 0.477 113.94 0.842 4.14 0.323 83.12 0.884 3.32 0.551
>65 29 83.97   3.27   109.83   3.54   86.00   2.74  
Tumor stage              
T1 and T2 13 85.14   3.75   114.23   3.73   91.38   4.00  
T3 11 89.98 0.79 3.43 0.215 107.64 0.462 3.17 0.81 78.34 0.866 2.39 0.033
T4 15 81.97   2.17   101.82   3.54   87.85   1.81  
Nodal status              
N0 5 74.61   5.60   105.13   4.25   67.82   4.40  
N1 13 79.73 0.556 2.91 0.03 106.47 0.774 4.23 0.028 77.85 0.23 2.88 0.094
N2 15 94.81   (N2 and N3)2,571   111.05   2.77   109.72   2.33  
N3 3 86.71     114.77   6.00   64.94   1.67  
metastatic status              
M0 11 90.68 0.403 4.64 0.013 121.84 0.036 3.90 0.137 90.40 0.77 4.35 0
M1 18 85.46   2.17   100.24   3.19   95.17   1.23  
Differentiation              
G1 and G2 5 81.93   4.20   118.89   5.25   83.67   3.75  
G3 24 85.77 0.82 3.05 0.624 108.33 0.432 3.31 0.105 87.57 0.691 2.23 0.304
G4 8 86.09   3.50   114.50   3.67   71.39   3.10  
pTNM stage              
I and II 12 79.10   4.08   109.53   3.91   73.67   4.06  
III 7 105.38 0.379 3.88 0.209 112.67 0.897 2.67 0.482 106.32 0.418 3.88 0.001
IV 19 69.66   2.50   96.80   3.68   46.35   0.95  
Lauren's classification              
intestinal type 12 69.30 0.105 3.42 0.538 109.93 0.719 4.50 0.06 80.17 0.773 3.80 0.535
diffuse type 22 91.26   3.03   112.63   3.41   84.80   3.41